<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00461643</url>
  </required_header>
  <id_info>
    <org_study_id>01/2007</org_study_id>
    <nct_id>NCT00461643</nct_id>
  </id_info>
  <brief_title>Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS</brief_title>
  <official_title>Comparison of Three Different Strategies for Treating Infertility in Anovulatory Women With Polycystic Ovary Syndrome: a Multicentre Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Magna Graecia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Magna Graecia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anovulatory infertility is a common feature of the polycystic ovary syndrome (PCOS). Even if
      several first-step treatments have been proposed for anovulatory infertile PCOS patients,
      very few data are available in literature regarding the best integrated strategy. In fact, a
      single compound could be effective as first-step approach but not or less useful when
      integrated in a more complex strategy.

      The goal of the current protocol will be to compare three different strategies for treating
      anovulatory infertility in PCOS patients having as primary end-point the multiple pregnancy
      rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients eligible will undergo baseline assessment consisting of antropometric, hormonal,
      and ultrasonographic assessments. Successively, patients enrolled will be allocated in three
      different strategies (strategy A, B, and C).

      A total of 184 infertile PCOS patients per arm will be enrolled and treated with three
      different integrated strategies: clomiphene followed by clomiphene plus metformin followed by
      gonadotropins (strategy A); metformin followed by metformin plus clomiphene followed by
      gonadotropins(strategy B); and metformin plus clomiphene followed by gonadotropins(strategy
      C).

      In all patients, the same regimen will be used to administered clomiphene, metformin, and
      gonadotropins.Both clomiphene and metformin will be administered at incremental doses in each
      case.Gonadotropins will be administrated to obtain a controlled ovarian stimulation using
      highly purified urinary FSH in a low-dose step-up protocol.

      During the study, the clinical and reproductive outcomes, and adverse experiences will be
      evaluated in each woman.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Multiple pregnancy rate</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ovulation rate</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abortion rate</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live-birth rate</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse-events</measure>
    <time_frame>15</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">552</enrollment>
  <condition>Anovulatory Infertility Related to Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Strategy A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clomiphene followed by clomiphene plus metformin followed by gonadotropins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Strategy B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin followed by metformin plus clomiphene followed by gonadotropins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Strategy C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin plus clomiphene followed by gonadotropins</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins</intervention_name>
    <arm_group_label>Strategy A</arm_group_label>
    <arm_group_label>Strategy B</arm_group_label>
    <arm_group_label>Strategy C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Polycystic ovary syndrome (using ESHRE/ARSM 2004 criteria)

        Exclusion Criteria:

          -  Age &lt;18 or &gt;35 years

          -  Severe obesity (BMI &gt;35)

          -  Neoplastic, metabolic, hepatic, and cardiovascular disorders or other concurrent
             medical illnesses

          -  Hypothyroidism, hyperprolactinemia, Cushing's syndrome, and non-classical congenital
             adrenal hyperplasia

          -  Current or previous (within the last six months) use of oral contraceptives,
             glucocorticoids, antiandrogens, antidiabetic and anti-obesity drugs or other hormonal
             drugs

          -  Previous use of ovulation induction agents

          -  Intention to start a diet or a specific program of physical activity

          -  No uterine bleeding after progesterone challenge test

          -  Organic pelvic diseases

          -  Previous pelvic surgery

          -  Suspected peritoneal factor infertility

          -  Tubal or male factor infertility or sub-fertility
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Palomba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics and Gynecology, University &quot;Magna Graecia&quot; of Catanzaro</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefano Palomba, MD</last_name>
    <phone>+39-0961.883234</phone>
    <email>stefanopalomba@tin.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>&quot;Pugliese&quot; Hospital</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Tomaino, MD</last_name>
      <phone>+39 0961 883234</phone>
      <email>angela.falbo@libero.it</email>
    </contact>
    <investigator>
      <last_name>Stefano Palomba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Pugliese&quot; Hospital</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Tomaino, MD</last_name>
      <phone>+39 0961 883234</phone>
      <email>zullo@unicz.it</email>
    </contact>
    <investigator>
      <last_name>Stefano Palomba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco Orio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Achille Tolino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pasquale Mastrantonio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Dale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ettore Cittadini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Riccardo Genazzani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pugliese-Ciaccio Hospital</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Palomba S, Orio F Jr, Falbo A, Manguso F, Russo T, Cascella T, Tolino A, Carmina E, Colao A, Zullo F. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 Jul;90(7):4068-74. Epub 2005 Apr 19.</citation>
    <PMID>15840746</PMID>
  </reference>
  <reference>
    <citation>Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ. 2006 Jun 24;332(7556):1485. Epub 2006 Jun 12.</citation>
    <PMID>16769748</PMID>
  </reference>
  <reference>
    <citation>Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Leppert PC, Myers ER; Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007 Feb 8;356(6):551-66.</citation>
    <PMID>17287476</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2007</study_first_submitted>
  <study_first_submitted_qc>April 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2007</study_first_posted>
  <last_update_submitted>April 5, 2013</last_update_submitted>
  <last_update_submitted_qc>April 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Magna Graecia</investigator_affiliation>
    <investigator_full_name>Stefano Palomba</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Anovulation</keyword>
  <keyword>Clomiphene citrate</keyword>
  <keyword>Infertility</keyword>
  <keyword>Metformin</keyword>
  <keyword>PCOS</keyword>
  <keyword>RCT</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Anovulation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

